Orionis Biosciences

About Orionis Biosciences

Orionis Biosciences is a biotechnology company focused on developing precision cancer medicines by reprogramming protein and immune cell interactions. The company designs and discovers novel drug modalities, including molecular glues, cytokines, and cell engagers, to harness the body's immune system against cancer with targeted, potentially less toxic therapies. Its platforms—Allo-Glue, A-Kine, and Multimodal Cell Engagers (MCEs)—enable targeted protein–protein, protein–cell, and cell–cell interactions to modulate disease pathways. With operations in the US and Belgium, Orionis collaborates with industry and academic partners to advance immuno-oncology programmes and first-in-human candidates such as ORB-011 and ORB-021 in oncology indications.